BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 10537341)

  • 21. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.
    Slovin SF; Ragupathi G; Musselli C; Olkiewicz K; Verbel D; Kuduk SD; Schwarz JB; Sames D; Danishefsky S; Livingston PO; Scher HI
    J Clin Oncol; 2003 Dec; 21(23):4292-8. PubMed ID: 14645418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies.
    Livingston P; Zhang S; Adluri S; Yao TJ; Graeber L; Ragupathi G; Helling F; Fleisher M
    Cancer Immunol Immunother; 1997 Jan; 43(6):324-30. PubMed ID: 9067403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor-cell killing by MAbs against fucosyl GM1, a ganglioside antigen associated with small-cell lung carcinoma.
    Brezicka FT; Holmgren J; Kalies I; Lindholm L
    Int J Cancer; 1991 Dec; 49(6):911-8. PubMed ID: 1660040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study).
    Giaccone G; Debruyne C; Felip E; Chapman PB; Grant SC; Millward M; Thiberville L; D'addario G; Coens C; Rome LS; Zatloukal P; Masso O; Legrand C
    J Clin Oncol; 2005 Oct; 23(28):6854-64. PubMed ID: 16192577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer.
    Sabbatini PJ; Ragupathi G; Hood C; Aghajanian CA; Juretzka M; Iasonos A; Hensley ML; Spassova MK; Ouerfelli O; Spriggs DR; Tew WP; Konner J; Clausen H; Abu Rustum N; Dansihefsky SJ; Livingston PO
    Clin Cancer Res; 2007 Jul; 13(14):4170-7. PubMed ID: 17634545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an immunogenic sLe(a) vaccine.
    Ragupathi G; Damani P; Srivastava G; Srivastava O; Sucheck SJ; Ichikawa Y; Livingston PO
    Cancer Immunol Immunother; 2009 Sep; 58(9):1397-405. PubMed ID: 19190907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy.
    Livingston PO; Hood C; Krug LM; Warren N; Kris MG; Brezicka T; Ragupathi G
    Cancer Immunol Immunother; 2005 Oct; 54(10):1018-25. PubMed ID: 15926079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New serum markers for small-cell lung cancer. I. The ganglioside fucosyl-GM1.
    Vangsted A; Drivsholm L; Andersen E; Pallesen T; Zeuthen J; Wallin H
    Cancer Detect Prev; 1994; 18(3):221-9. PubMed ID: 8076384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines.
    Helling F; Shang A; Calves M; Zhang S; Ren S; Yu RK; Oettgen HF; Livingston PO
    Cancer Res; 1994 Jan; 54(1):197-203. PubMed ID: 8261439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biochemical and immunochemical analysis of gangliosides of human small cell lung carcinoma: production of monoclonal antibodies against a unique marker of small cell lung carcinoma, ganglioside Fuc GM1.
    Fuchs BB; Avrova NF; Starosvetskaya NA; Boltovskaya MN; Zaraisky EI; Karpova OB; Reznikova EV; Soldatova LN; Stepanov AA
    Biotechnol Appl Biochem; 1988 Jun; 10(3):273-86. PubMed ID: 2840097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.
    Kirkwood JM; Ibrahim JG; Sosman JA; Sondak VK; Agarwala SS; Ernstoff MS; Rao U
    J Clin Oncol; 2001 May; 19(9):2370-80. PubMed ID: 11331315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Small cell lung cancer is not associated with the presence of anti-fucosyl-GM1 ganglioside autoantibodies reactive in immunoenzymatic test.
    Adler G; Pacuszka T; Lewartowska A; Rowinska E; Oblakowski P; Panasiewicz M
    Lung Cancer; 2001 Dec; 34(3):383-5. PubMed ID: 11714535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The immune response to disialoganglioside GD3 vaccination in normal dogs: a melanoma surface antigen vaccine.
    Milner RJ; Salute M; Crawford C; Abbot JR; Farese J
    Vet Immunol Immunopathol; 2006 Dec; 114(3-4):273-84. PubMed ID: 17027091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2.
    Foon KA; Sen G; Hutchins L; Kashala OL; Baral R; Banerjee M; Chakraborty M; Garrison J; Reisfeld RA; Bhattacharya-Chatterjee M
    Clin Cancer Res; 1998 May; 4(5):1117-24. PubMed ID: 9607568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Establishment of monoclonal antibodies specific for ganglioside GM1: detection of ganglioside GM1 in small cell lung carcinoma cell lines and tissues.
    Watarai S; Kiura K; Shigeto R; Shibayama T; Kimura I; Yasuda T
    J Biochem; 1994 Nov; 116(5):948-54. PubMed ID: 7896755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside.
    Chapman PB; Williams L; Salibi N; Hwu WJ; Krown SE; Livingston PO
    Vaccine; 2004 Jul; 22(21-22):2904-9. PubMed ID: 15246627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coexpression of ganglioside antigen Fuc-GM1, neural-cell adhesion molecule, carcinoembryonic antigen, and carbohydrate tumor-associated antigen CA 50 in lung cancer.
    Brezicka FT; Olling S; Bergman B; Berggren H; Engström CP; Hammarström S; Holmgren J; Larsson S; Lindholm L
    Tumour Biol; 1992; 13(5-6):308-15. PubMed ID: 1337798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines.
    Ragupathi G; Cappello S; Yi SS; Canter D; Spassova M; Bornmann WG; Danishefsky SJ; Livingston PO
    Vaccine; 2002 Jan; 20(7-8):1030-8. PubMed ID: 11803062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of DHBcAg as a potent carrier protein comparable to KLH for augmenting MUC1 antigenicity.
    Gathuru JK; Koide F; Ragupathi G; Adams JL; Kerns RT; Coleman TP; Livingston PO
    Vaccine; 2005 Sep; 23(39):4727-33. PubMed ID: 15978705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant.
    McCaffery M; Yao TJ; Williams L; Livingston PO; Houghton AN; Chapman PB
    Clin Cancer Res; 1996 Apr; 2(4):679-86. PubMed ID: 9816218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.